|
Session 212: Frontiers in Pharmacology and Toxicology |
|
|
Day 2: Morning, May 12, 2022 |
|
|
Chair |
Dr. Cecil Pace-Asciak, Professor and Senior Scientist Emeritus, The Hospital for Sick Children, Canada
|
|
Co-Chair |
Dr. Niels Decher, Professor, Institute for Physiology and Pathophysiology, Vegetative Physiology, Philipps University Marburg, Germany |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-09:00 |
Title: Photopharmacology of TRPC Channels - High Precision Immunomodulation and Beyond Dr. Klaus Groschner, Professor, Chair of Biophysics, Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Medical University of Graz, Austria |
|
09:00-09:25 |
Title: TBD |
|
09:25-09:50 |
Title: Neurogenesis Promoted by the Green Tea Amino Acid Theanine for Brain Health |
|
09:50-10:15 |
Speech Opportunity Available |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Title: TBD Dr. Niels Decher, Professor, Institute for Physiology and Pathophysiology, Vegetative Physiology, Philipps University Marburg, Germany |
|
10:55-11:20 |
Speech Opportunity Available |
|
11:20-11:45 |
Title: Nonclinical Program to Support Nusinersen in Treating Patients with Spinal Muscular Atrophy Dr. Kenneth S. Loveday, Principal Investigator of Toxicology, Preclinical Safety Department, Biogen, USA |
|
11:45-12:10 |
Title: Triterpenoid Antitumor Agents on ATL Cells and their Mechanism Dr. Yasuhiro Yoshida, Department of Immunology and Parasitology, School of Medicine, University of Occupational and Environmental Health, Japan |
|
Session 222: Novel Analytical Technology in Drug Discovery |
|
|
Day 2: Morning, May 12, 2022 |
|
|
Chair |
Dr. Andreas Seidl, Chief Operating Officer, Leukocare AG, Germany |
|
Co-Chair |
Dr. Barun K. De, Professor of Pathology, University of Arizona, USA |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-09:00 |
Keynote Speech Title: The Problem with Chemical Noise in Substance Analysis in Doping Control Dr. Mats Larsson, Professor, Department of Physics, Stockholm University, Sweden |
|
09:00-09:25 |
Title: Biophysical and Bioinformatic Tools to Support Developability and Formulability Assessment of Biologics Dr. Andreas Seidl, Chief Operating Officer, Leukocare AG, Germany |
|
09:25-09:50 |
Title: TBD Dr. Andy Moreno, Genetic Detection Systems Engineer, HSG-AME Certified Laboratories, USA |
|
09:50-10:15 |
Title: TBD Dr. Linda Yi, Sr. Scientist, Analytical Development, Biogen, USA |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Title: TBD Dr. Barun K. De, Professor of Pathology, University of Arizona, USA |
|
10:55-11:20 |
Title: Quality by Design Based Development and Validation of HPLC Method for Simultaneous Estimation of Paclitaxel and Vinorelbine Tartrate in Dual Drug Loaded Liposomes Dr. Smita Bonde, Associate Professor, School of Pharmacy & Technology Management, SVKMs NMIM, India |
|
11:20-11:45 |
Title: Parenteral Nutrition Admixtures for Pediatric Patients Compounded with Highly Refined Fish Oil-Based Emulsion: Assessment of Physicochemical Stability Dr. Germana Bersani, Consulting Pharmacist, University of Bologna, Italy |
|
11:45-12:10 |
Speech Opportunity Available |
|
Session 312: CNS and Neurodegenerative Drug Targets |
|
|
Day 2: Morning, May 12, 2022 |
|
|
Chair |
Dr. Jack T. Rogers, Associate Professor, Harvard University; Director of Neurochemistry, Massachusetts General Hospital, USA |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-09:00 |
Speech Opportunity Available |
|
09:00-09:25 |
Title: TBD Dr. Jack T. Rogers, Associate Professor, Harvard University; Director of Neurochemistry, Massachusetts General Hospital, USA |
|
09:25-09:50 |
Title: Effect of Phosphodiesterase (1B, 2A, 9A and 10A) Inhibitors on Central Nervous System Cyclic Nucleotide Levels in Rats and Mice Dr. Jie Chen, Scientist, Dart NeuroScience LLC, USA |
|
09:50-10:15 |
Title: GABAB Receptor Trafficking and Interacting Proteins: Targets for the Development of Highly Specific Therapeutic Strategies to Treat Neurological Disorders? Dr. Musadiq Ahmad Bhat, Postdoctoral Scientist, University of Zurich, Switzerland |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Speech Opportunity Available |
|
10:55-11:20 |
Speech Opportunity Available |
|
11:20-11:45 |
Title: Urinary Kynurenine as a Biomarker for Parkinson's Disease Mr. Yong-Peng Yu, Physician-in-Charge, Weihai Central Hospital, Qingdao University, China |
|
11:45-12:10 |
Speech Opportunity Available |
|
Session 322: New Achievements in Drug Design and Synthesis |
|
|
Day 2: Morning, May 12, 2022 |
|
|
Chair |
Dr. Ryszard Ostaszewski, Professor of Organic Chemistry, Institute of Organic Chemistry, Polish Academy of Sciences, Poland |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-09:00 |
Title: Generative Models to New Compounds: Multi-Parametric Optimisation and Synthetic Accessibility Dr. Yann Gaston-Mathe, Co-founder and CEO, Iktos, USA |
|
09:00-09:25 |
Title: Photoswitchable Diarylethene-modified Peptides: Promising Drug Candidates for Photopharmacology Dr. Igor V. Komarov, Scientific Advisor, Lumobiotics GmbH, Germany |
|
09:25-09:50 |
Title: The Studies on Ciprofloxacin Functionalization Using Multicomponent Reactions and Their Evaluation as a New Therapeutic Agents Against Multidrug Resistant Tumors Dr. Ryszard Ostaszewski, Professor of Organic Chemistry, Institute of Organic Chemistry, Polish Academy of Sciences, Poland |
|
09:50-10:15 |
Title: Incorporating Continuous Flow Technology in Exploratory Process Development Dr. Bryan Li, Research Fellow, Chemical R & D of Pharmaceutical Science Small Molecule Division, Pfizer Inc., USA |
|
10:15-10:30 |
Coffee Break |
| 10:30-10:55 |
Speech Opportunity Available |
| 10:55-11:20 |
Title: Rational Design and Synthesis of Drug Candidate TRPM8 antagonist: Antinociceptive Effect in Acute and Chronic Pain Preclinical Models Dr. Andrea Aramini, VP, Director of Drug Discovery, Head of Research & Early Development, Dompe SpA, Italy |
| 11:20-11:45 |
Title: TBD Dr. Salvatore Guccione, Professor, Central Drug Research Institute, Italy |
| 11:45-12:10 |
Title: Innovative Chemistry Toward Novel Tetrapyrrolic Macrocycles: Photodynamic Therapy and Imaging of Cancer Dr. Teresa M. V. D. Pinho e Melo, Professor, Department of Chemistry, University of Coimbra, Portugal |
| 12:10-12:35 |
Title: Mitochondria as Multitarget to Design Insecticides Dr. Stelia Carolina Mendez-Sanchez, Assistant Professor, School of Chemistry, Industrial University of Santander, Colombia |
|
Session 412: CNS Diseases |
|
|
Day 2: Morning, May 12, 2022 |
|
|
Chair |
Dr. Istvan J. E. Boksay, Clinical Professor, New York University, USA |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-09:00 |
Keynote Speech Title: How Can We Prevent Dementia; the Effect of Comorbid Diseases on Cognitive Decline Dr. Istvan J. E. Boksay, Clinical Professor, New York University, USA |
|
09:00-09:25 |
Title: Determination of the Intramuscular Motor Endpointsfor Effective Administration of Botulinum Toxin in the Treatment of Spasticity Dr. Alexandr Kovalenko, Military Medical Academy, Russia |
|
09:25-09:50 |
Title: Global Emerging Role of Rehabilitation |
|
09:50-10:15 |
Title: MOG Antibody Disease in Children Dr. Liwen Wu, Associate Professor, Xiangya Hospital, Central South University, China |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:55 |
Title: Diagnosis and Treatment of Posterior Sacroiliac Complex Pain: A Systematic Review with Comprehensive Analysis of the Published Data Dr. Wade King, Interventional Pain Physician, Mayo Private Hospital, Australia |
|
10:55-11:20 |
Title: TBD Dr. Vitalii Kovalchuk, Professor, Saint-Petersburg State-financed Healthcare Institution "N.A. Semashko city hospital", Russia |
|
11:20-11:45 |
Speech Opportunity Available |
|
11:45-12:10 |
Title: PPARβ/δ Antagonism Counteracts Pro-oxidant Effects Induced by 6-OHDA in both in Vivo and in Vitro Models of Parkinson's Disease Dr. Vanessa Castelli, Research Associate, University of L'Aquila, Italy |
|
Session 422: Development of Therapeutic Antibodies, Vaccines and Antibodyomes |
|
|
Day 2: Morning, May 12, 2022 |
|
|
Chair |
Dr. Methal Albarghouthi, Director, Analytical Sciences, Biopharmaceutical Development, AstraZeneca, USA |
|
Co-Chair |
Dr. Kelly Y. Zhou, Founder & Chief Scientific Officer, AbboMax, Inc, USA |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-08:55 |
Title: Non-clinical and Clinical Development of Monoclonal Antibodies with an Innovative and Cost-effective Manufacturing Process Dr. Jaap Wieling, CSO, BiosanaPharma BV, the Netherlands |
|
08:55-09:15 |
Title: Anti-VLDL Receptor Monoclonal Antibodies as a Potential Therapeutics for Treatment of Myocardial Ischemia-reperfusion Injury Dr. Leonid Medved, Professor of Biochemistry and Molecular Biology, Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, USA |
|
09:15-09:35 |
Title: Well-Characterization of Co-formulation of Therapeutic Antibodies Dr. Methal Albarghouthi, Director, Analytical Sciences, Biopharmaceutical Development, AstraZeneca, USA |
|
09:35-09:55 |
Title: Our Experience in Developing Therapeutic Antibodies and Vaccines in Last 5 Decades Dr. Suresh Jadhav, Executive Director, Serum Institute of India Pvt. Ltd., India |
|
09:55-10:15 |
Title: TBD Dr. Kelly Y. Zhou, Founder & Chief Scientific Officer, AbboMax, Inc, USA |
|
10:15-10:30 |
Coffee Break |
|
10:30-10:50 |
Title: Detection of Organophosphate Bound Butytylcholinesterase Using a Monoclonal Antibody Dr. Yoon-Won Kim, Professor, Hallym University; CEO, ImmuneMed, South Korea |
|
10:50-11:10 |
Title: Recombinant Targeting Moyeties Selectively Deliver Powerful Cytotoxins to Cancer Cells Dr. Michele Marzola, Co-Founder and CEO, Interceptin srl, Italy |
|
11:10-11:30 |
Title: Fighting SARS-CoV-2 and other Infectious Diseases with Recombinant Antibodies Dr. Michael Hust, Professor for Biotechnology, Technische Universität Braunschweig, Germany |
|
11:30-11:50 |
Title: Non-cognate Ligands of Broadly Neutralizing Antibody Paratopes as Potential Vaccine Immunogens Dr. Petr Maly, Head of Research Group, Institute of Biotechnology, The Czech Academy of Sciences, Czech Republic |
|
11:50-12:10 |
Speech Opportunity Available |
|
Session 441: New Challenges in Future Pharma Manufacturing |
|
|
Day 2: Morning, May 12, 2022 |
|
|
Chair |
Dr. Stefan R. Schmidt, COO/Head of Operations, BioAtrium AG, Switzerland |
|
Time |
|
|
08:30-08:35 |
Chair's Introduction |
|
08:35-09:00 |
Keynote Speech Title: Influence of Production Process Methodology and Scale on Polypeptide Drug Quality: Case study on GLP-1 Derivatives Dr. Arne Staby, Scientific VP, CMC Project Management, Novo Nordisk A/S, Denmark |
|
09:00-09:25 |
Title: Process Intensification: Current Approaches and Future Strategies for Biologics Manufacturing Dr. Stefan R. Schmidt, COO/Head of Operations, BioAtrium AG, Switzerland |
|
09:25-09:50 |
Title: Roadmap for Practical Use of Continuous Manufacturing System “iFactory“ by 2030 Mr. Yousuke Maezawa, Business Marketing Division Business Produce Department, Yokogawa Solution Service corporation, Japan |
|
09:50-10:15 |
Speech Opportunity Available |
|
10:15-10:30 |
Coffee Break |
Session 442: Frontiers in Novel Biosimilars Day 3: Morning, May 12, 2022 Chair Dr. John D. Chappell, Application & Service Director EMEA and Asia Pacific, Gyros Protein Technology, UK Time 08:30-08:35 Chair's Introduction 08:35-08:55 Keynote Speech Title: Landscape of Biosimilars Dr. S. D. Ravetkar, Executive Director, Serum Institute of India Pvt Ltd., India 08:55-09:15 Title: Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs Dr. John D. Chappell, Application & Service Director EMEA and Asia Pacific, Gyros Protein Technology, UK 09:15-09:35 Title: What is Enough in Biosimilars Development? Dr. Andreu Soldevila, CEO, Syna Therapeutics, Spain 09:35-09:55 Title: Statistical Challenges in Biosimilar Development Dr. Dejun Tang, Senior Vice President, Firma Clinical Research, USA 09:55-10:15 Title: TBD Dr. Zsolt Hollo, Head, Center of Biological Business Development and Technology, EGIS Pharmaceuticals, Hungary 10:15-10:30 Coffee Break 10:30-10:50 Title: A Legal Update on the US Biosimilars Market Dr. Paul Calvo, Director, Sterne, Kessler, Goldstein & Fox P.L.L.C., USA 10:50-11:10 Title: The Value of Generic Medicines to Discovery Molecules Dr. Brian Tempest, Independent Non Executive Director, Glenmark Holdings SA, UK 11:10-11:30 Title: Development of Innovative Potency Assays for Biosimilars Dr. Michael G. Tovey, Managing Director, EuroDiagnostica Biomonitor, France 11:30-11:50 Title: Development of Biosimilars Cost Effectively for Timely Availability and Affordability Dr. Niranjan M Kumar, CEO & President of American Biosources Inc. USA 11:50-12:10 Speech Opportunity Available
|
Session 213: Drug Metabolism and Drug Interactions |
|
|
Day 2: Afternoon, May 12, 2022 |
|
|
Chair |
Dr. Urban Fagerholm, Founder & CEO, PROSILICO, Sweden |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Keynote Speech Title: Lysosomal Trapping: Methods of study and Implications for Advanced Drug Discovery Dr. Andreas Reichel, VP, Head of Research Pharmacokinetics, Bayer Pharma AG, Germany |
|
14:00-14:25 |
Title: TBD Dr. Urban Fagerholm, Founder & CEO, PROSILICO, Sweden |
|
14:25-14:50 |
Speech Opportunity Available |
|
14:50-15:15 |
Title: Use of PBPK for Complex Drug-drug-gene Interactions Prediction in Clinical Settings Dr. Youssef Daali, Head of the Laboratory of Clinical Pharmacology, Geneva University Hospitals, Switzerland |
|
15:15-15:30 |
Coffee Break |
|
Session 223: Nanotechnology in Drug Discovery |
|
|
Day 2: Afternoon, May 12, 2022 |
|
|
Chair |
Call for Chair |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Speech Opportunity Available |
|
14:00-14:25 |
Speech Opportunity Available |
|
14:25-14:50 |
Speech Opportunity Available |
|
14:50-15:15 |
Speech Opportunity Available |
|
15:15-15:30 |
Coffee Break |
|
Session 313: Autoimmune and Inflammation Drug Targets |
|
|
Day 2: Afternoon, May 12, 2022 |
|
|
Chair |
Dr. José Luis Muñoz-Carrillo, Faculty of Odontology, Cuauhtémoc Aguascalientes University, México |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Keynote Speech Title: From DAMPs Model to Phase II Clinical Trial Targeting GPCR19 to Regulate NLRP3 Inflammasome Dr. Seung-Yong Seong, Professor, Seoul National University College of Medicine, South Korea |
|
14:00-14:25 |
Title: Resiniferatoxin Promotes Adult Worms Expulsion in Trichinella spiralis-infected Rats by Th2 Immune Response Modulation Dr. José Luis Muñoz-Carrillo, Faculty of Odontology, Cuauhtémoc Aguascalientes University, México |
|
14:25-14:50 |
Title: Resiniferatoxin Treatment Exhibits Anti-inflammatory Properties in a Murine Model of Lipopolysaccharide-induced Inflammation Dr. Israel Alvarez-Barreto, Faculty of Odontology, Cuauhtémoc Aguascalientes University, México |
|
14:50-15:15 |
Title: Effect of Treatment with Resiniferatoxin in an Experimental Model of Pulpal Inflammatory in Mice Dr. Jazmín Monserrat Vargas-Barboza, Faculty of Odontology, Cuauhtémoc Aguascalientes University, México |
|
15:15-15:30 |
Coffee Break |
|
15:30-15:55 |
Title: VEGF Blockers Ameliorate Granulomatous Inflammation Dr. Matyas Sandor, Professor, Department of Pathology, University of Wisconsin-Madison, USA |
|
15:55-16:20 |
Speech Opportunity Available |
|
16:20-16:45 |
Title: TBD Dr. Lara Baticic, Assistant Professor, Department of Medical Chemistry, Biochemistry and Clinical Chemistry, Faculty of Medicine, University of Rijeka, Croatia |
|
16:45-17:10 |
Speech Opportunity Available |
|
Session 323: Lead Discovery: Screening and Optimization |
|
|
Day 2: Afternoon, May 12, 2022 |
|
|
Chair |
Call for Chair |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Speech Opportunity Available |
|
14:00-14:25 |
Speech Opportunity Available |
|
14:25-14:50 |
Speech Opportunity Available |
|
14:50-15:15 |
Title: Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care Dr. Vallerie Gordon, Assistant Professor, CancerCare Manitoba, Canada |
|
15:15-15:30 |
Coffee Break |
|
Session 413: Infectious Diseases |
|
|
Day 2: Afternoon, May 12, 2022 |
|
|
Chair |
Call for Chair |
|
Co-Chair |
Dr. Peter M. Keller, Deputy Head of Diagnostics, University of Bern, Switzerland |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Speech Opportunity Available |
|
14:00-14:25 |
Title: Glenmark's Pioneering Clinical Development Work to Fight the COVID-19 Pandemic Dr. Monika Tandon, Senior Vice President & Head, Glenmark Pharmaceuticals, India |
|
14:25-14:50 |
Title: The Anti-influenza Agent about the Synthesis, and Influenza Patients Trend under the Sudden Spread of the Coronavirus 2019-2020 Season Here, Takasaki, Gunma, Japan Dr. Tomoko Mineno, Professor, Laboratory of Medicinal Chemistry, Faculty of Pharmacy, Takasaki University of Health and Welfare, Japan |
|
14:50-15:15 |
Title: TBD Dr. Pierre-Francois Laterre, Head of the ICU, St Luc University Hospital, Catholic University of Louvain, Belgium; Consultant, Ferring Pharmaceuticals, Belgium |
|
15:15-15:30 |
Coffee Break |
|
15:30-15:55 |
Title: TBD Dr. Peter M. Keller, Deputy Head of Diagnostics, University of Bern, Switzerland |
|
15:55-16:20 |
Title: TBD Dr. Lucija Peterlin Masic, Professor, The Chair of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ljubljana, Slovenia |
|
16:20-16:45 |
Title: Village Health Workers Role in Managing Infectious Diseases at the Community Level Dr. Maseabata Ramathebane, Senior Lecturer, Pharmacy Department, Faculty Of Health Sciences, National University of Lesotho, Italy |
|
16:45-17:10 |
Title: Continuous Activation of Kinases, A Novel Mode of Action for Antimicrobial Agent Dr. Wei Huang, Associate Professor, Bacteriology & Antibacterial Resistance Surveillance Laboratory, Shenzhen Institute of Respiratory Diseases, Shenzhen People's Hospital, China |
|
Session 414: Cardiovascular Diseases |
|
|
Day 2: Afternoon, May 12, 2022 |
|
|
Chair |
Dr. Michael Markert, Vice President and Global Head of CardioMetabolic Diseases Research, Boehringer Ingelheim, Germany |
|
Co-Chair |
Dr. Jia Li, Professor, Department of Pediatric Cardiology, Children’s Hospital Affiliated to Capital Institute of Pediatrics, China |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-13:55 |
Keynote Speech Title: TBD Dr. Gerhard M. Artmann, Professor, Institute of Neurophysiology, University of Cologne, Germany |
|
13:55-14:15 |
Title: Screening for Congenital Heart Disease in Asymptomatic and Critically Ill Newborns Using Echocardiography and Follow-up at High Altitude in China Dr. Jia Li, Professor, Department of Pediatric Cardiology, Children’s Hospital Affiliated to Capital Institute of Pediatrics, China |
|
14:15-14:35 |
Title: Kv7 Channels in Smooth Muscle as Therapeutic Targets for Vascular and Airway Diseases Dr. Kenneth Byron, Professor Emeritus, Loyola University Chicago Stritch School of Medicine, USA |
|
14:35-14:55 |
Title: Models of Preclinical Cardiovascular Safety Evaluation Dr. Michael Markert, Vice President and Global Head of CardioMetabolic Diseases Research, Boehringer Ingelheim, Germany |
|
14:55-15:15 |
Title: Cardiac Fulcrum and Myocardial Torsion Dr. Jorge Carlos Trainini, Head of Department, Presidente Peron Hospital, Universidad a Distancia de Madrid, Argentina |
|
15:15-15:30 |
Coffee Break |
|
15:30-15:50 |
Title: Producing Therapeutic Levels of Nitric Oxide from Air for Treating Pulmonary and Cardiovascular Diseases Dr. Binglan Yu, Assistant Professor, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA |
|
15:50-16:10 |
Title: Managing the Acute Coronary Syndrome Patient: Evidence Based Recommendations for Anti-Platelet Therapy Dr. Michael G. Clark, Adjunct Professor, Touro Worldwide University; Adjunct Clinical Associate Professor, Touro College School of Health Sciences; Clinical Assistant Professor, Chatham University, USA |
|
16:10-16:30 |
Title: LDL-Receptor: 45 years of Research and 5 Strategies to Enhance Its Function Dr. Enrique C. Morales Villegas, Director and Principal Investigator, Aguascalientes Cardiometabolic Research Center, Mexico |
|
16:30-16:50 |
Speech Opportunity Available |
|
16:50-17:10 |
Speech Opportunity Available |
|
Session 415: Diabetes and Other Metabolic Disorders |
|
|
Day 2: Afternoon, May 12, 2022 |
|
|
Chair |
Dr. John Knight, Professorial Fellow, The George Institute for Global Health, Australia |
|
Co-Chair |
Dr. Marianna Rachmiel, Director, Pediatric Endocrinology Unit, Shamir Medical Center (Assaf Harofeh), Israel |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Title: New Drug Development in Type-2 Diabetes Mellitus Dr. Vivek Lal, Associate Professor of Pharmacology, College of Medicine, King Faisal University, Saudi Arabia |
| 14:00-14:25 |
Title: Affordable Dialysis for the Developing World Dr. John Knight, Professorial Fellow, The George Institute for Global Health, Australia |
|
14:25-14:50 |
Title: Real Life Experience of Diabetes Technologies in Pediatric and Adolescents Population with Type 1 Diabetes Dr. Marianna Rachmiel, Director, Pediatric Endocrinology Unit, Shamir Medical Center (Assaf Harofeh), Israel |
|
14:50-15:15 |
Title: Intranasal Glucagon. Good News for people with Hypoglycemia Dr. Antonio E. Pontiroli, Professor, Department of Health Science, University of Milan, Italy |
|
15:15-15:30 |
Coffee Break |
|
15:30-15:55 |
Speech Opportunity Available |
|
15:55-16:20 |
Speech Opportunity Available |
|
16:20-16:45 |
Speech Opportunity Available |
|
16:45-17:10 |
Speech Opportunity Available |
|
Session 443: CMO/CRO and Outsourcing Services |
|
|
Day 3: Afternoon, May 12, 2022 |
|
|
Chair |
Dr. Claire Thompson, CEO, Agility Life Sciences, UK |
|
Time |
|
|
13:30-13:35 |
Chair's Introduction |
|
13:35-14:00 |
Speech Opportunity Available |
|
14:00-14:25 |
Title: TBD Dr. Claire Thompson, CEO, Agility Life Sciences, UK |
|
14:25-14:50 |
Speech Opportunity Available |
|
14:50-15:15 |
Speech Opportunity Available |
|
15:15-15:30 |
Coffee Break |
© 2003-2022 All rights reserved by BITeomics |